Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.
The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long hist...